These treatments may include vemurafenib (BRAF inhibitor) for melanoma patients with V600E/V600K mutation in the BRAF gene [114], Neratinib (HER2 TKI) [115], trastuzumab (HER2 antibody) [116] and pertuzumab (HER2 antibody) [117] for breast cancer patients with amplification and/or overexpression of the HER2 gene, and erlotinib (EGFR TKI) for non-small cell lung cancer patients with exon 19 deletion or L858R mutation in the EGFR gene [118]. The gene discussed is BRAF; the disease is breast carcinoma.